EngenderHealth, Inc. – Trademark Portfolio
Entity Type: 03
EngenderHealth, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ENGENDERHEALTH. The owner is based in New York, NY.
Thirteenth Floor
440 Ninth Avenue
New York, NY 10001
Showing of trademarks Trademarks
Trademark Classifications
EngenderHealth, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Scientific and technological services; industrial analysis and research services
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does EngenderHealth, Inc. have?
EngenderHealth, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned, 2 cancelled.
What trademark classes does EngenderHealth, Inc. file in?
EngenderHealth, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 36 (Insurance & Financial), Class 38 (Telecommunications). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.
What are EngenderHealth, Inc.'s most well-known trademarks?
EngenderHealth, Inc.'s registered trademark portfolio includes well-known marks such as ENGENDERHEALTH. These are among 2 currently registered trademarks in the portfolio.
What is EngenderHealth, Inc.'s trademark registration success rate?
EngenderHealth, Inc. has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.